Susan Vogt Appointed to Board of Directors of Anika Therapeutics

From Startup Anika Therapeutics

Link to Full Article:

Long-Serving DirectorSteven Wheeler to Retire from Board in
February 2019
BEDFORD, Mass.–(BUSINESS WIRE)–Oct. 24, 2018–
Therapeutics, Inc. (NASDAQ: ANIK) (“Anika” or the “Company”), a
global, integrated orthopedic and regenerative medicines company
specializing in therapeutics based on its proprietary hyaluronic
acid (“HA”) technology, announced that, effective immediately,
Anika’s Board of Directors has appointed Susan Vogt as an independent

Ms. Vogt most recently served as Chief Executive Officer and Director of
Aushon Biosystems, a venture-backed company with a novel multiplex
immunoassay platform. She previously served as President, CEO, and a
Director of SeraCare Life Sciences, a publicly traded life sciences
company focused on human diagnostics and therapeutics. From 2001 to
2005, she served as President of the Biopharmaceutical Division of
Millipore Corporation (now MilliporeSigma), where she began her career
in 1981. She earned a Master of Business Administration with high honors
in Finance from Boston University, where she received a Distinguished
Alumni Award in 2009, and a Bachelor of Arts degree from Brown

The Company also announced that Steven Wheeler, who has served as a
director of Anika since 1993 and currently chairs the Board’s Governance
and Nominating Committee, has notified the Board of his intention to
retire as of February 8, 2019.

“This is another important step in the transition of Anika’s leadership
that began with the appointment of Joseph Darling as CEO in March of
this year,” said Joseph L. Bower, Chairman of the Board of Directors,
“and it demonstrates our continued commitment to strong corporate
governance and refreshment of the Board.”

“Sue brings to Anika more than thirty-five years of experience in the
global life science research, pharmaceutical, biotech and clinical
diagnostics industries, and we are excited she is joining our Board,”
said Joseph G. Darling, President and CEO of Anika. “We are confident
that Anika will benefit greatly from her input and guidance as we
continue to advance our ongoing initiatives and enhance our global
commercial reach.”

“Anika has a strong foundation with a deep pipeline and a diverse
commercial portfolio, and I am excited to work with the other directors
and management team to continue advancing the Company’s important work.
I look forward to leveraging my experience as we continue to advance
Anika’s clinical programs, deliver important therapeutic options for
patients and drive profitable growth to enhance value for Anika
shareholders,” Ms. Vogt said.

About Anika Therapeutics, Inc.
Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated orthopedic
and regenerative medicines company based in Bedford, Massachusetts.
Anika is committed to improving the lives of patients with degenerative
orthopedic diseases and traumatic conditions with clinically meaningful
therapies along the continuum of care, from palliative pain management
to regenerative tissue repair. The Company has over two decades of
global expertise developing, manufacturing, and commercializing more
than 20 products based on its proprietary hyaluronic
acid (HA) technology. Anika’s orthopedic medicine portfolio includes ORTHOVISC®,
and CINGAL®,
which alleviate pain and restore joint function by replenishing depleted
a solid HA-based scaffold to aid cartilage repair and regeneration. For
more information about Anika, please visit

View source version on
Source: Anika Therapeutics, Inc.

For Investor Inquiries:Anika Therapeutics, Inc.Sylvia
Cheung, 781-457-9000Chief Financial OfficerorFor Media
Inquiries:Pure Communications, Inc.Sonal Vasudev,

Please visit their site for more information: Anika

All,Biotechnology,Healthcare News,Startup News
2018-10-24 19:47:38